focus -WSS

focus

author：fashion 2025-08-12 09:13:05 - browse：34862

Illumina, the leading maker of DNA sequencing machines, said Sunday that it would divest Grail, the developer of a multi-cancer screening test, which it bought over the objections of regulators in the U.S. and Europe in August 2021.

Illumina said the decision to spin Grail off followed a Friday decision of the U.S. Fifth Circuit Court of Appeals, which held that the merger was anti-competitive. It said that it would divest Grail either by selling it to another company or listing it on capital markets, consistent with an order from the European Commission, and that it aims to finalize the terms of the deal by the end of the second quarter of 2024.

The decision opens what should be the final chapter in one of the most disastrous attempted mergers in biotech history. Illumina, a storied name that had delivered investors strong returns over two decades, spun out Grail in 2016 in order to raise money to fund the company’s work. Then, it announced plans to re-acquire the firm for $7.1 billion in Sept. 2020.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： UnitedHealth sued over use of algorithm in Medicare Advantage plans

WSS

Readout Newsletter: Zepbound, Valneva's vaccine, and more

Asbestos, a deadly carcinogen, banned by EPA

FDA cancer chief on how to get things done: ‘Don’t tell anybody'

Health AI adoption puts security, privacy startups on investors' radar

U.K. not yet recommending Vertex's CRISPR therapy for sickle cell

Plastic surgeons increase patient psychiatric screenings

Wikipedia

focus

entertainment

Hepatitis C has a cure — but many Americans still lack access to it

Asbestos, a deadly carcinogen, banned by EPA

Tori Bowie and the unacceptable rates of Black maternal death

Today's health inequities arise from racist U.S. history, say experts

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Experimental asthma app from Apple and Anthem shows promise

Hepatitis C has a cure — but many Americans still lack access to it

Methadone treatment changes are coming. Do they go far enough?

Jerome Adams on the need for new antivirals for Covid

CVS, Rite Aid closures threaten to worsen pharmacy deserts

hotspot

Readout Newsletter: Geron, Novo Nordisk, WuXi updates

Ohio still needs to do more to protect the right to abortion

UnitedHealth sued over use of algorithm in Medicare Advantage plans

I was wrong about Geron's blood cancer drug. Now, is it a takeover target?

I was wrong about Geron's blood cancer drug. Now, is it a takeover target?

5 to watch: Tech startups trying to solve health care's staffing crisis

Wikipedia

knowledge

explore

Wikipedia